Amgen Inc. (NASDAQ:AMGN) registered a 2.73% increase, still its new closing price is 18.39% up from the company’s 1 year high of 175.66.It posted 1.61% gains in previous 5 sessions and is now the subject of 12 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 25 stock analysts following this company have an average price target at $181.78, with individual PT in the $158.51-$218.00 range. The shares moved at $157.16, implying that brokerage firms see shares gaining about 8.73% in twelve months time.
Amgen Inc. (AMGN) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 7.49% rise year to date. A VP, Finance and CAO at Amgen Inc. (AMGN) offloaded shares in a transaction closed on Tuesday August 02, 2016. Such Annette Louise sold 3,000 shares in the company at $174.59 each and collected $523,001 in proceeds. Such Annette Louise now owns 7,183 shares in the company after this transaction. A EVP, Operations in the company, Balachandran Madhavan, disclosed a transaction on Wednesday May 04, 2016 that ended up generating $4,623,001 from the sale of 30,000 shares at $154.12 per share.
Amgen Inc. (NASDAQ:AMGN) Upcoming Results on Tap
Amgen Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $3.08 in that period. Sales during the quarter are predicted to arrive at $5.63 billion.
Earnings surprise history: Last quarter, the company posted approximately $5.81 billion in revenue and EPS of $3.02. The mean forecast was for $5.73 billion and $2.79 a share, respectively. One quarter earlier, revenue for the stock was at $5.69 billion, with earnings at $2.84/share.
Amgen Inc. (AMGN) Brokerage Update
Amgen Inc. (AMGN) is in Credit Suisse’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Outperform by Credit Suisse, according to news reported on Tuesday December 20, 2016.Another important research note was issued by Argus on Friday January 25, 2013.The firm upgraded AMGN to Buy from Hold. Over the last six months and over the last three months, the shares of Amgen Inc. (AMGN), have changed -7.09% and -0.48%, respectively.